INAB
In8bio Inc
NASDAQ: INAB · HEALTHCARE · BIOTECHNOLOGY
$1.07
-3.60% today
Updated 2026-07-29
Market cap
$11.51M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.54
Dividend yield
—
52W range
$1 – $3
Volume
0.1M
WallStSmart proprietary scores
29
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C7.0
Quality
B+3.0
Profitability
D5.0
Valuation
C+4/9
Piotroski F-Score
Moderate
-3.7
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$6.25
+484.11%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.10x — low leverage
Risks
- Altman Z -3.69 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-4.96M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-27.42M | $-30.01M | $-30.44M | $-19.44M | $-5.09M |
| EPS | — | — | — | — | $-2.54 |
| Free cash flow | $-27.83M | $-23.94M | $-24.25M | $-12.71M | $-4.96M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
In8bio Inc trades at $1.07. Our Smart Value Score of 29/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -3.69, it sits in the distress.
Frequently asked questions
What is In8bio Inc's stock price?
In8bio Inc (INAB) trades at $1.07.
Is In8bio Inc overvalued?
In8bio Inc carries a Smart Value Score of 29/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of In8bio Inc (INAB)?
The 12-month analyst consensus target is $6.25, about 484.1% above the current $1.07. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
In8bio Inc's Altman Z-Score is -3.69, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-103.60%
Beta0.22
50D MA$1.46
200D MA$1.73
Shares out0.01B
Float0.01B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—